BrainsWay Ltd. (BWAY) Stock
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About BrainsWay Ltd.
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BrainsWay Ltd. is headquartered in IL.
BrainsWay Ltd. (BWAY) stock trades at $16.56 with a market capitalization of $649.53M. The stock is valued at a price-to-earnings (P/E) ratio of 72.48, price-to-book of 8.22, price-to-sales of 10.83. Over the past 52 weeks the stock has ranged between $5.68 and $17.35, and currently trades 4.6% below its 52-week high.
On profitability, BrainsWay Ltd. generates a return on equity (ROE) of 12.28%, above the typical market average, return on capital employed of 6.54%, an operating margin of 10.09%, a net profit margin of 14.57%.
Official website: www.brainsway.com